Insmed reported $806.66M in Loan Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
DBV Technologies DBVT:US 0 0
Acelrx Pharmaceuticals ACRX:US $ 3.04M 1.97M
Alimera Sciences ALIM:US $ 36.24M 6.84M
Biomarin Pharmaceutical BMRN:US $ 1080.06M 0.98M
Cytokinetics CYTK:US $ 197.08M 54.24M
Dynavax Technologies DVAX:US $ 220.76M 0.27M
Gilead Sciences GILD:US $ 25183M 4M
Heron Therapeutics HRTX:US $ 149.13M 0.05M
Insmed INSM:US $ 806.66M 225.97M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NVS:US $ 24373M 150M
Ophthotech OPHT:US $ 0M 0M
Regeneron Pharmaceuticals REGN:US $ 2700.4M 720.4M
Sarepta Therapeutics SRPT:US $ 1098.85M 1.97M
Seattle Genetics SGEN:US $ 0M 0M
Ultragenyx Pharmaceutical RARE:US $ 0M 0.41M
Vertex Pharmaceuticals VRTX:US $ 495.5M 14.3M